drugset / Trial / NCT00003274
Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery
Phase 2
Completed
48 enrolled
University of Southern California
National Cancer Institute (NCI) · collab
RandomizedTreatment
Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known what preparation of vaccine therapy is most effective for treating melanoma. PURPOSE: Randomized phase II trial to study the effectiveness of tyrosinase/gp100 peptide vaccine in treating patients who have stage II melanoma that can be removed by surgery.
Timeline
- Start
- 1998-03
- Primary completion
- 2001-09
- Completion
- 2002-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | gp100 antigen | Peptide | — | Subcutaneous |
| Subject | sargramostim | Protein / enzyme biologic | — | Subcutaneous |
| Subject | tyrosinase peptide | Peptide | — | Subcutaneous |
| Background | incomplete Freund's adjuvant | Other / unclassified | — | Subcutaneous |